TBL2 and Its Role in Breast Cancer
Author Information
Author(s): Lu Xiuqing, Zhang Chao, Zhu Lewei, Wang Sifen, Zeng Lijun, Zhong Wenjing, Wu Xuxia, Yuan Qi, Tang Hailin, Cui Shien, Tan Yeru, Li Yuehua, Wei Weidong
Primary Institution: Sun Yat-sen University Cancer Center
Hypothesis
TBL2 promotes tumorigenesis in breast cancer through PRMT5/WDR77-mediated AKT activation.
Conclusion
The study identifies TBL2 as a potential therapeutic target in breast cancer due to its role in promoting AKT activation and cell proliferation.
Supporting Evidence
- TBL2 is selectively overexpressed in breast cancer tissues compared to normal tissues.
- High TBL2 expression correlates with poor prognosis in breast cancer patients.
- TBL2 promotes AKT phosphorylation, enhancing breast cancer cell proliferation.
- Knocking down TBL2 reduces breast cancer cell growth.
- TBL2 acts as a scaffold for PRMT5 and WDR77, enhancing their interaction.
Takeaway
TBL2 is a protein that helps breast cancer cells grow. If we can stop TBL2, we might be able to slow down or stop the cancer.
Methodology
The study used real-time PCR, western blotting, immunohistochemistry, and Kaplan-Meier survival analysis to assess TBL2 expression and its effects on breast cancer cell proliferation.
Limitations
The specific domains responsible for TBL2's interactions with PRMT5 and WDR77 were not identified.
Participant Demographics
200 patients with invasive ductal carcinoma from Sun Yat-sen University Cancer Center.
Statistical Information
P-Value
p=0.003 for RFS, p=0.023 for OS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website